Drug
EZN 2968 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
National Cancer Institute (NCI) (1) · Hoffmann-La Roche (1) · Enzon Pharmaceuticals, Inc. (1)
Studies
Open first, then newest update. How each study uses EZN 2968 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver MetastasesCompletedPhase 1National Cancer Institute (NCI)NCT01120288Written as EZN-2968
- A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)CompletedPhase 1Hoffmann-La RocheNCT02564614Written as RO7070179
- Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or LymphomaCompletedPhase 1Enzon Pharmaceuticals, Inc.NCT00466583Written as Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)